Adult Dosing
Tinea cruris, Tinea corporis
- Apply cream (45 g/wk)/lotion (45 mL/wk) to the affected skin bid, in the morning and evening
- Max: 45 g/wk (cream) or 45 mL/wk (lotion)
Notes:- Reassess diagnosis if no improvement is seen within 2 weeks of therapy
- Avoid using with occlusive dressings
Tinea pedis
- Apply cream (45 g/wk)/lotion (45 mL/wk) to the affected skin bid, in the morning and evening
- Max: 45 g/wk (cream) or 45 mL/wk (lotion)
Notes:- Reassess diagnosis if no improvement is seen within 4 weeks of therapy
- Avoid using with occlusive dressings
Pediatric Dosing
- Safety and effectiveness in pediatric patients <17 yrs of age have not been established
Tinea cruris, Tinea corporis
- Apply cream (45 g/wk)/lotion (45 mL/wk) to affected skin bid, in morning and evening
- Max: 45 g/wk (cream) or 45 mL/wk (lotion)
Notes:- Reassess diagnosis if no improvement is seen within 2 weeks of therapy
- Avoid using with occlusive dressings
Tinea pedis
- Apply cream (45 g/wk)/lotion (45 mL/wk) to affected skin bid, in morning and evening
- Max: 45 g/wk (cream) or 45 mL/wk (lotion)
Notes:- Reassess diagnosis if no improvement is seen within 4 weeks of therapy
- Avoid using with occlusive dressings
[Outline]
- Systemic absorption of topical corticosteroids may be associated with reversible HPA axis suppression, manifestations of Cushing syndrome, hyperglycemia, and glucosuria
- Use of more than one corticosteroid-containing product at the same time is associated with increased total systemic glucocorticoid exposure. Periodically evaluate patients receiving higher dose of a potent topical steroid to a large surface or to areas under occlusion for evidence of HPA axis suppression by using the urinary-free cortisol and ACTH stimulation tests. On presence of HPA axis suppression, make an attempt to discontinue the drug, to reduce the frequency of application, or to substitute with a less potent steroid. Recovery of HPA axis function is generally prompt and complete upon withdrawal of this drug
- Application of dose 7 g/day for 14 days (bid) may be associated with reduced plasma levels of adrenal cortical hormones in the mornings
- Pediatric patients may be more susceptible to systemic toxicity
- On occurrence of irritation, discontinue topical corticosteroids and institute appropriate therapy
- Contraindicated for the treatment diaper dermatitis
Caution: Use cautiously in
- Skin infections or reinfection
Pregnancy Category:C
Breastfeeding: Topical betamethasone has not been evaluated during breastfeeding. It is unlikely that short-term application would pose a risk to the breastfed infant. Use the least potent drug on the smallest area of skin possible. Ensure that the infant's skin does not come into direct contact with the areas of skin that have been treated. Use lower potency corticosteroids on the nipple or areola where the infant could directly ingest the drugs from the skin. Apply only water-miscible cream or gel products to the breast because ointments may expose the infant to high levels of mineral paraffins via licking. Wipe off any topical corticosteroid prior to nursing if it is applied to the breast or nipple area. It is unlikely that a topical clotrimazole adversely affects the breastfed infant. Any excess cream or ointment should be removed from the nipples before nursing. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACTlast accessed 19 February 2011). Manufacturer advises caution.
US Trade Name(s)
US Availability
clotrimazole/betamethasone (generic)
- CRE: 0.05%/1%
- LOTN: 0.05%/1%
Lortisone (clotrimazole/betamethasone)
- CRE: 0.05%/1%
- LOTN: 0.05%/1%
Canadian Trade Name(s)
Canadian Availability
Lotriderm (clotrimazole/betamethasone)
UK Trade Name(s)
UK Availability
Australian Trade Name(s)
Australian Availability
[Outline]